RxDoctor Payments Data

Nupur Gosalia, MD

Family Medicine · Oceanside, CANPI 1528223542

Payments from drug & device makers

$2,251in general payments, 2019–2025

Across 112 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$683
  • GSK$525
  • AbbVie$326
  • Lilly USA, LLC$128
  • Novo Nordisk$117
  • Bayer$51
  • plus $421 from 14 others

What the payments were for

  • Food & beverage$2,251100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,251 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$21,964
Medicare patients
78
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$51,473
EliquisApixaban33$41,587
MounjaroTirzepatide22$26,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,221
XareltoRivaroxaban27$19,081
JanuviaSitagliptin Phosphate18$19,030
MyrbetriqMirabegron14$9,156
Aripiprazole28$3,353
Levothyroxine Sodium251$3,037
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,562
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen91$2,542
Gabapentin95$2,489
Omeprazole105$2,172
Metoprolol Succinate117$2,004
Bupropion XlBupropion Hcl57$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$51,47346 claims
PfizerEliquis$44$41,58733 claims
Lilly USA, LLCMounjaro$128$26,11522 claims
GSKTrelegy Ellipta$525$19,22118 claims
Johnson & JohnsonXarelto$33$19,08127 claims
MerckJanuvia$43$19,03018 claims
Astellas Pharma US IncMyrbetriq$18$9,15614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →